However, studies have shown that treatment with IFN-β or TGF-β blockade can polarize neutrophils to an “N1” antitumor phenotype, characterized by enhanced tumor cell phagocytosis and recruitment of T cells via CXCL10 [151, 152]. This evidence concerns the gene CXCL10 and neoplasm.